Celsion (CLSN) says ThermoDox missed its primary endpoint in a Phase III trial for liver cancer...

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Celsion (CLSN) says ThermoDox missed its primary endpoint in a Phase III trial for liver cancer patients. (PR)